Financhill
Sell
50

LAB Quote, Financials, Valuation and Earnings

Last price:
$1.33
Seasonality move :
1.41%
Day range:
$1.30 - $1.35
52-week range:
$0.92 - $2.41
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.91x
P/B ratio:
1.05x
Volume:
1.9M
Avg. volume:
2.2M
1-year change:
-32.65%
Market cap:
$476.8M
Revenue:
$174.4M
EPS (TTM):
-$0.35

Analysts' Opinion

  • Consensus Rating
    Standard BioTools has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 1 Hold rating, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $2.38, Standard BioTools has an estimated upside of 79.92% from its current price of $1.32.
  • Price Target Downside
    According to analysts, the lowest downside price target is $2.25 representing 100% downside risk from its current price of $1.32.

Fair Value

  • According to the consensus of 3 analysts, Standard BioTools has 79.92% upside to fair value with a price target of $2.38 per share.

LAB vs. S&P 500

  • Over the past 5 trading days, Standard BioTools has underperformed the S&P 500 by -1.92% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Standard BioTools does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Standard BioTools revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Standard BioTools reported revenues of $40.8M.

Earnings Growth

  • Standard BioTools has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Standard BioTools reported earnings per share of -$0.07.
Enterprise value:
219.1M
EV / Invested capital:
--
Price / LTM sales:
2.91x
EV / EBIT:
--
EV / Revenue:
1.29x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.77x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$79.8M
Return On Assets:
-19.76%
Net Income Margin (TTM):
-78.24%
Return On Equity:
-26.52%
Return On Invested Capital:
-24.87%
Operating Margin:
-74.26%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Income Statement
Revenue $96.6M $126.8M $169.7M $45.5M $40.8M
Gross Profit $37.1M $62.3M $79.8M $24.2M $19.7M
Operating Income -$95.8M -$86.3M -$126.3M -$38.7M -$30.3M
EBITDA -$113.5M -$68.5M -$106.6M -$25.8M -$22M
Diluted EPS -$1.66 -$1.01 -$0.35 -$0.27 -$0.07
Period Ending 2021-03-31 2022-03-31 2023-03-31 2024-03-31 2025-03-31
Balance Sheet
Current Assets $96.3M $73.2M $194.9M $547.6M $344M
Total Assets $305.2M $271.9M $371.7M $777.7M $579.6M
Current Liabilities $53.5M $47.2M $43.8M $121.6M $56.2M
Total Liabilities $182.3M $249.8M $468.8M $200.4M $125M
Total Equity $122.9M $22.1M -$97.2M $577.3M $454.6M
Total Debt $53.8M $100M $65.1M $55M $299K
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Cash Flow Statement
Cash Flow Operations -$82.3M -$97.3M -$111.3M -$62.5M -$30.3M
Cash From Investing -$44.1M $295.2M $59.7M $318.1M $14.6M
Cash From Financing $210.1M -$24M -$82.9M -$19.7M -$46K
Free Cash Flow -$86.2M -$99.9M -$123.9M -$63.3M -$35.3M
LAB
Sector
Market Cap
$476.8M
$33.5M
Price % of 52-Week High
54.77%
48.01%
Dividend Yield
0%
0%
Shareholder Yield
10.28%
-0.97%
1-Year Price Total Return
-32.65%
-33.61%
Beta (5-Year)
1.543
0.621
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $1.33
200-day SMA
Sell
Level $1.47
Bollinger Bands (100)
Buy
Level 1.05 - 1.25
Chaikin Money Flow
Buy
Level 694.8K
20-day SMA
Buy
Level $1.22
Relative Strength Index (RSI14)
Buy
Level 59.01
ADX Line
Buy
Level 20.57
Williams %R
Neutral
Level -61.3636
50-day SMA
Buy
Level $1.13
MACD (12, 26)
Buy
Level 0.30
25-day Aroon Oscillator
Buy
Level 44
On Balance Volume
Neutral
Level 429K

Financial Scores

Sell
Altman Z-Score (Annual)
Level (0.273)
Sell
CA Score (Annual)
Level (-2.3273)
Sell
Beneish M-Score (Annual)
Level (-1.7026)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.5653)
Buy
Piotroski F Score (Annual)
Level (4)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (4)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.

Stock Forecast FAQ

In the current month, LAB has received 2 Buy ratings 1 Hold ratings, and 0 Sell ratings. The LAB average analyst price target in the past 3 months is $2.38.

  • Where Will Standard BioTools Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Standard BioTools share price will rise to $2.38 per share over the next 12 months.

  • What Do Analysts Say About Standard BioTools?

    Analysts are divided on their view about Standard BioTools share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Standard BioTools is a Sell and believe this share price will drop from its current level to $2.25.

  • What Is Standard BioTools's Price Target?

    The price target for Standard BioTools over the next 1-year time period is forecast to be $2.38 according to 3 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.

  • Is LAB A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Standard BioTools is a Buy. 2 of 3 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of LAB?

    You can purchase shares of Standard BioTools via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Standard BioTools shares.

  • What Is The Standard BioTools Share Price Today?

    Standard BioTools was last trading at $1.33 per share. This represents the most recent stock quote for Standard BioTools. Yesterday, Standard BioTools closed at $1.32 per share.

  • How To Buy Standard BioTools Stock Online?

    In order to purchase Standard BioTools stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Microsoft Be a $5 Trillion Stock?
Will Microsoft Be a $5 Trillion Stock?

Microsoft’s market capitalization sits near $3.73 trillion today. To clear the…

Where Will C3.ai Stock Be in 1 Year?
Where Will C3.ai Stock Be in 1 Year?

C3 .ai (NYSE: AI) has been the poster child for “hype versus execution.”…

What Is the Ceiling for IONQ Stock?
What Is the Ceiling for IONQ Stock?

IonQ (NYSE:IONQ) is a quantum computing startup that, like many…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
58
INKT alert for Jul 12

MiNK Therapeutics [INKT] is up 727.94% over the past day.

Buy
51
NEGG alert for Jul 12

Newegg Commerce [NEGG] is up 74.03% over the past day.

Buy
68
ATRO alert for Jul 12

Astronics [ATRO] is up 16.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock